Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03020095 | Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan | PHASE2 | COMPLETED | 38 | — | — | Aug 1, 2015 | Feb 1, 2017 | Oct 22, 2020 | - | — |
SVR12, defined as undetectable HCV RNA 12 weeks after the last day of study drug administration.
| Arm | Type | Description |
|---|---|---|
| Ravidasvir,Danoprevir/r,RBV | EXPERIMENTAL | Participants will receive Ravidasvir 200mg plus Ritonavir boosted Danoprevir 200/200mg,and Ribavirin 1000/1200mg daily for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| Ravidasvir | DRUG | Ravidasvir 200mg tablet administered orally once daily |
| Danoprevir | DRUG | Danoprevir 100mg tablet administered orally twice daily |
| Ritonavir | DRUG | Ritonavir 100mg tablet administered orally twice daily |
| Ribavirin | DRUG | Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally |
Inclusion Criteria: * Willing and able to provide written informed consent * Chronic HCV infection (≥6 months) , HCV RNA ≥ 1 × 104 IU/mL * Never received prior-treatment for HCV with interferon, RBV, or other direct-acting or host-targeting antivirals for HCV * Chronic liver disease consistent with...